NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Lumos Pharma
Abramson Cancer Center at Penn Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aravive, Inc.